SGLT2 Inhibitors (e.g., Dapagliflozin)
Treatment for Chronic Kidney Disease Due To Hypertension
Typical Dosage: Dapagliflozin 10mg daily
Effectiveness
95%
Safety Score
65%
Clinical Trials
30
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Dapagliflozin 10mg daily
Time to Effect
3-6 months for significant renoprotection
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
19(Treat 19 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,500
Monitoring:$1,000
Side Effect Mgmt:$150
Total Annual:$6,650
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$50,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$14,778
Comparison vs Standard care (ACEi/ARB)
Cost Difference
+$6,650/year
More expensive
QALY Difference
+0.80 QALYs
Better outcomes
Dominance
No dominance
SGLT2 Inhibitors (e.g., Dapagliflozin) Outcomes
for Chronic Kidney Disease Due To Hypertension
Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+45%
Common Side Effects
Genital mycotic infections
+8%
Urinary tract infections
+4%
Hypotension/Volume depletion
+2%
Euglycemic diabetic ketoacidosis (rare)
+0.1%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov